FDA Approves Unknown Drug — MYLAN

Mylan received FDA approval on March 20 to market the generic version of this product, a move that is poised to allow the company to capitalize on peak sales projections while gaining a foothold in this specific therapeutic market segment. This authorization enables Mylan to enter the commercial landscape faster than anticipated, driving incremental revenue growth during the five-year market exclusivity period for the brand name inhibitor.